FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...
BOSTON, June 13, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical...
Delivered comprehensive oral presentation on both cohorts of the clinical trial, including previously announced...
Received FDA Type A meeting minutes related to previously announced clinical hold FDA acknowledged newly...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...
Recently announced positive results for second cohort of Phase 2 clinical trial of ZGN-1061 Company...
BOSTON, May 02, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.